Turning the Tide

on Zytiga®-Resistant Metastatic
Castration-Resistant Prostate Cancer (mCRPC)

Adding Onvansertib to Daily Zytiga is Increasing the Duration of Response to Treatment and Progression-Free Survival

New Therapeutic Options are Needed to Overcome Resistance to SOC Androgen Receptor Signaling Inhibitors (ARSi)

Resistance develops to treatment with standard of care ARSi’s within 9-15 months.

ARSi’s offer a median overall survival (mOS) benefit of only ~4 months.

No effective treatment options are available for the up to 40% of mCRPC patients with an AR-V7 mutation.

Limited options for patients once resistant to abiraterone

New treatment options are needed to extend the duration of response to ARSi’s and increase overall survival.

Onvansertib + Abiraterone (Zytiga®)
Demonstrate Synergy in Abi-Resistant Model

Onvansertib + Abiraterone (Zytiga®)
Significantly Increases Apoptotic Cell Death¹

Why onvansertib is a promising option for
mCPRC: Overcoming resistance to Zytiga

Onvansertib in combination with Zytiga (abiraterone) demonstrates synergy in 
mCRPC and significantly increases the arrest of tumor cell division.

Onvansertib in Combination with FOLFIRI/Avastin® is Demonstrating Safety and Efficacy in KRAS-Mutated Metastatic Colorectal Cancer

Phase 2 multi-center open-label clinical trial NCT03414034

“This data shows that adding onvansertib to abiraterone in metastatic castration-resistant prostate cancer patients with an early resistance to abiraterone validates pre-clinical studies and shows potential as a new therapeutic option.”

Dr. David Einstein,
principal investigator at the
Beth Israel Deaconess Medical Center

Assessment of Preliminary Efficacy and Duration of Response

Two-fold increase in disease control achieved with greater dose-density schedule in Arm C

Treatment Response and Duration​

26% (5/19) DCR at 12 weeks in patients with at least 1 AR alteration
associated with abiraterone resistance

Our Clinical Programs

KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.

Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Leveraging the synergy of onvansertib to increase duration and response of overall survival.

Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.